A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner

Nature Biotechnology

Volumn 27, Issue 12, 2009, Pages 1186-1190

  Schellenberger, Volker ^a   Wang, Chia Wei ^a   Geething, Nathan C ^a   Spink, Benjamin J ^a   Campbell, Andrew ^a   To, Wayne ^a   Scholle, Michael D ^a   Yin, Yong ^a   Yao, Yi ^a   Bogin, Oren ^a   Cleland, Jeffrey L ^b   Silverman, Joshua ^a   Stemmer, Willem P C ^a  

^a Amunix Inc   (United States)

^b Versartis Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOMETRIC SCALING; BIOLOGICAL ACTIVITIES; DOSING FREQUENCY; GENERIC APPROACH; HUMAN GROWTH HORMONE; HYDROPHOBIC AMINO ACIDS; IMMUNOGENICITY; IN-VIVO; PROTEIN DRUGS; PROTEIN THERAPEUTICS; RECOMBINANT POLYPEPTIDES; RESIDENCE TIME; SIDE EFFECT;

AMINATION; AMINES; AMINO ACIDS; DRUG INTERACTIONS; ORGANIC ACIDS; PEPTIDES; RADIOACTIVITY;

PLASMA STABILITY;

AMINO ACID; BLOOD CLOTTING FACTOR 7; EXENATIDE XTEN; EXENDIN 4; GLUCAGON; GLUCAGON XTEN; GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN XTEN; HUMAN GROWTH HORMONE; HUMAN GROWTH HORMONE XTEN; HYBRID PROTEIN; PLACEBO; UNCLASSIFIED DRUG; XTEN PROTEIN;

ALLOMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STABILITY; FEMALE; GENE FUSION; HUMAN; HYDROPHOBICITY; IMMUNOGENICITY; IN VIVO STUDY; MONKEY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN STABILITY; SINGLE DRUG DOSE;

ANIMALS; MICE; PEPTIDES; PROTEIN ENGINEERING; PROTEINS; RECOMBINANT FUSION PROTEINS;

MUS;

EID: 71849085755     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1588     Document Type: Article

References (29)

1. Kochendoerfer, G. Chemical and biological properties of polymer-modifed proteins. Expert Opin. Biol. Ther. 3, 1253-1261 (2003).
2. Fishburn, C.S. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 97, 4167-4183 (2008).
3. Ryan, S.M., Mantovani, G., Wang, X., Haddleton, D.M. & Brayden, D.J. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin. Drug Deliv. 5, 371-383 (2008).
4. Dhalluin, C. et al. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. Bioconjug. Chem. 16, 504-517 (2005).
5. Gaertner, H.F. & Offord, R.E. Site-specifc attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjug. Chem. 7, 38-44 (1996).
6. Shaunak, S. et al. Site-specifc PEGylation of native disulfde bonds in therapeutic proteins. Nat. Chem. Biol. 2, 312-313 (2006).
7. Huang, L, Gough, P.C. & Defelippis, M.R. Characterization of poly(ethylene glycol) and PEGylated products by LC/MS with postcolumn addition of amines. Anal. Chem. 81, 567-577 (2009).
8. Bendele, A., Seely, J., Richey, C, Sennello, G. & Shopp, G. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol. Sci. 42, 152-157 (1998).
9. Richter, A.W. & Akerblom, E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modifed proteins. Int. Arch. Allergy Appl. Immunol. 70, 124-131 (1983).
10. Sroda, K. et al. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell. Mol. Biol. Lett. 10, 37-47 (2005).
11. Sinigaglia, F. & Hammer, J. Motifs and supermotifs for MHC class II binding peptides. J. Exp. Med. 181, 449-451 (1995).
12. Alvarez, P., Buscaglia, C.A. & Campetella, O. Improving protein pharmacokinetics by genetic fusion to simple amino acid sequences. J. Biol. Chem. 279, 3375-3381 (2004).
13. Schlapschy, M. et al. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Eng. Des. Sel. 20, 273-284 (2007).
14. Byetta package insert. (Amylin Pharmaceuticals, San Diego, 2009).
15. Drucker, D.J. et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372, 1240-1250 (2008).
16. Uversky, V.N. What does it mean to be natively unfolded? Eur. J. Biochem. 269, 2-12 (2002).
17. Cindric, M. et al. Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites. J. Pharm. Biomed. Anal. 44, 388-395 (2007).
18. ELSPAR package insert. (Merck & Co. Inc, Whitehouse Station, New Jersey, 2009).
19. Baggio, L.L., Huang, Q., Brown, T.J. & Drucker, D.J. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53, 2492-2500 (2004).
20. Glucagon package insert. (Eli Lilly & Co., Indianapolis, 2009).
21. Tucker, M. Very-low-dose glucagon may prevent nocturnal hypoglycemia. Pediatr. News 41, 58 (2007).
22. Harris, J.M. & Chess, R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214-221 (2003).
23. He, X.H., Shaw, P.C. & Tam, S.C. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci. 65, 355-368 (1999).
24. Shiffman, M.L. Pegylated interferons: what role will they play in the treatment of chronic hepatitis C? Curr. Gastroenterol. Rep. 3, 30-37 (2001).
25. Ai, G. et al. Single-and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. Int. J. Pharm. 353, 56-64 (2008).
26. Chez, R.A. et al. Glucagon metabolism in nonhuman primate pregnancy. Am. J. Obstet. Gynecol. 120, 690-696 (1974).
27. Huang, Y. et al. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia Pastoris. J. Pept. Sci. 14, 588-595 (2008).
28. Mahmood, I. Application of a l lometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv. Drug Deliv. Rev. 59, 1177-1192 (2007).
29. Folta-Stogniew, E. & Williams, K.R. Determination of molecular masses of proteins in solution: Implementation of an HPLC size exclusion chromatography and laser light scattering service in a core laboratory. J. Biomol. Tech. 10, 51-63 (1999).